Ludwig Presence at 2017 Society for Immunotherapy of (SITC) Annual Meeting

Abstract/Presentation Presentation/Abstract Title & Ludwig Scientist(s) Affiliation(s) Keywords Category Time

FRIDAY, NOVEMBER 10

Science Behind the Therapy: Arlene Sharpe (session Ludwig Harvard N/A Mechanisms of Efficacy & Introduction (9:25 - 9:35am) chair) Toxicity

SATURDAY, NOVEMBER 11

Clinical Management General Concepts of Toxicity Michael Postow Ludwig MSK N/A (Physician/Nurse/Pharmacy Management (3:45 - 4:15pm) Track)

Clinical Management Panel Discussion: Management of Michael Postow Ludwig MSK N/A (Physician/Nurse/Pharmacy Complex Adverse Events (4:35 - Track) 5:00pm)

SUNDAY, NOVEMBER 12

Genetically Modified Cell Updates in CAR T cells (8:30 - Crystal Mackall Ludwig Stanford N/A Therapy 8:55am) Hot Topic Symposium: Advancing the Field: Can Emerging Topics (10:55 - Michael Postow Ludwig MSK N/A Physics and Mathematics 11:15am) Impact the Development of Tumor Immunotherapy? Hot Topic Symposium: Advancing the Field: Can Challenges in Clinical Michael Postow Ludwig MSK N/A Physics and Mathematics Development (11:15 - 11:35am) Impact the Development of Tumor Immunotherapy? *scientist is lead author **scientist is senior author 1 Ludwig Presence at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

ORAL PRESENTATIONS

Myeloid cells | Immune Re-educating macrophage suppression | Metabolism | Cellular Metabolism and through glutamine metabolism- Ping-Chih Ho Ludwig Lausanne Monocyte/Macrophage | Tumor Antitumor Immunity mediated metabolic and infiltrating lymphocytes (TILs) | epigenetic reprogramming Tumor microenvironment

Pooled 3-year overall survival data from phase II and phase III trials Michael Postow*, Jedd Checkpoint blockade | Clinical Combination Therapy (IO/IO, Ludwig MSK of nivolumab (NIVO) combined Wolchok trial | Solid tumors IO/Standard of Care, IO/Other) with ipilimumab (IPI) in advanced

Tumor infiltrating lymphocytes (TILs) | | Solid tumors | Biomarkers | Immune Multiplex three-dimensional Stephen Kron* Ludwig contexture | Tumor Emerging Models and Imaging optical mapping of tumor immune microenvironment | Targeted microenvironment therapy | Antibody | Checkpoint blockade | Radiotherapy

ABSTRACTS

Phase 1/2 study of in situ Antibody | Solid tumors | vaccination with tremelimumab + Sunita Hack, Paul Checkpoint blockade | TLR | intravenous (IV) durvalumab + Schwarzenberger, Toni Clinical Trials Tumor microenvironment | Clinical Trials - in progress poly ICLC in patients with select Ricciardi, Mary Macri, Aileen Management Team Tumor infiltrating lymphocytes relapsed, advanced with Ryan, Ralph Venhaus (TILs) | Clinical trial measurable, biopsy-accessible tumors

*scientist is lead author **scientist is senior author 2 Ludwig Presence at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sadna Budhu*, Rachel Phosphatidylserine targeting Checkpoint blockade | Giese, Roberta Zappasodi, antibody in combination with Radiotherapy | Tumor Luis Felipe Campesato, Ludwig MSK Combination Therapy tumor radiation and immune infiltrating lymphocytes (TILs) | Aditi Gupta, Jedd Wolchok, checkpoint blockade promotes Solid tumors Taha Merghoub** anti-tumor activity in mouse B16 melanoma Neurotoxicity in patients with metastatic solid tumors treated Bianca Santomasso*, irAE Management: Clinical Ludwig MSK Checkpoint blockade with immune checkpoint inhibitors: Margaret Callahan** Care and Best Practices a single institution retrospective analysis Antigen presenting cells | Class IIa HDAC inhibition Costimulation | Myeloid cells | promotes an anti-tumor Jennifer Guerriero*, Sara Tumor Microenvironment Ludwig Harvard Tumor microenvironment | macrophage phenotype that Schad, Anthony Letai** (Mechanisms and Therapies) Monocyte/Macrophage | Solid induces breast tumor regression tumors and inhibits metastasis Dmitriy Zamarin*, Anton Upregulation of PD-L1 in tumor Oseledchyk, Mathieu Checkpoint blockade | Tumor Oncolytic Viruses and microenvironment is a resistance Ludwig MSK Gigoux, Taha Merghoub, microenvironment | Vaccine Intratumoral Therapies mechanism for oncolytic virus Jedd Wolchok** immunotherapy Roberta Zappasodi*, Sadna Budhu, Michael Postow, Biomarkers | Checkpoint Cailian Liu, Hong Zhong, Non-conventional inhibitory CD4+ blockade | Immune monitoring | Mechanisms of Resistance to Billel Gasmi, Daniel Ludwig MSK Foxp3- PD-1 hi T cells as a Immune suppression | T cell | Immunotherapy Hirschhorn-Cymerman, biomarker of immune checkpoint Tumor evasion Taha Merghoub, Jedd blockade activity Wolchok**

*scientist is lead author **scientist is senior author 3 Ludwig Presence at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Daniel Hirschhorn*, Bilel

Gasmi, Levi Mark Mangarin, Immune adjuvant | Solid tumors T cell immunotherapies trigger Sadna Budhu, Yang Xia, | Immune toxicity | Tumor Immune Modulation, Ludwig MSK innate immunity and aseptic Hong Zhong, Cailian Liu, stroma | Tumor Cytokines, and Antibodies inflammation leading to potent anti- Roberta Zappasodi, Jedd microenvironment tumor and off-targets effects Wolchok, Taha Merghoub**

Optimizing targeted therapy and Hyejin Choi*, Tarik Silk, Checkpoint blockade | Targeted immune checkpoint blockade Taha Merghoub, Jedd Ludwig MSK Combination Therapy therapy | T cell therapy in Kras mutant lung Wolchok cancer Isoform specific TGF-β inhibition Aditi Gupta*, Sadna Budhu, Tumor microenvironment | in combination with radiation Rachel Giese, Gerd Ritter, Targeted therapy | Solid tumors Immune Modulation, Ludwig MSK therapy as a novel immune Jedd Wolchok, Taha | Cytokine | Antibody | Immune Cytokines, and Antibodies therapeutic approach to cancer Merghoub** suppression therapy Tumor microenvironment | T-cell metabolic insufficiency Luis Felipe Campesato*, Metabolism | Solid tumors | Cellular Metabolism and explains the dysfunctional Sadna Budhu, Jedd Ludwig MSK Tumor infiltrating lymphocytes Antitumor Immunity immune response in renal cell Wolchok, Taha Merghoub (TILs) carcinoma Cytokine | Tumor-derived PGD2 and NKp30- Dominique Vanhecke, Leukemia/Lymphoma | Tumor B7H6 engagement drives an Cellular Metabolism and George Coukos, Laurent Ludwig Lausanne microenvironment | immunosuppressive ILC2-MDSC Antitumor Immunity Derré, Camilla Jandus** | MDSC | axis in acute promyelocytic NK/NK T cell leukemia Adoptive immunotherapy | Engineering adoptive T cell Ludwig Scientific Tumor microenvironment | Philip Greenberg* Cellular Therapy Approaches therapy for efficacy in ovarian Advisory Committee Solid tumors | T cell | Immune cancer suppression | Tumor antigens

*scientist is lead author **scientist is senior author 4 Ludwig Presence at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Phase 1/1b, first-in-human study Checkpoint blockade | Clinical of the PI3K-gamma inhibitor IPI- study | Solid tumors | Tumor Michael Postow, Jedd 549 as monotherapy and Ludwig MSK microenvironment | Clinical Trials - in progress Wolchok** combined with nivolumab in Chemotherapy | Clinical trial | patients with advanced solid Monocyte/Macrophage tumors

*scientist is lead author **scientist is senior author 5